Health-related quality of life (HRQL) has been the cornerstone of outcomes research for three decades and increasingly is an important focus in human health measurement where instruments are developed to measure chronic disease in people through its impact on HRQL. An important goal of evidence-based medicine has been to incorporate patient reported HRQL scales to better assess clinical outcome.
It’s predictably sad that those parts of the UK with the most overweight adults also have the most overweight pets, […]
We are all used to seeing a stiff old dog, with a greying muzzle, hobbling along – gamely trying to keep up with its owner on its lead. Dog lovers might stop, kindly ruffle its ears and think “poor old thing”. Often though, it’s osteoarthritis and not age, causing the stiffness.
Canine obesity is increasing in prevalence in the UK and raises concerns about dog welfare. This study compares the health-related quality of life (HRQL) of dogs of varying body condition: overweight and obese (BCS 4 and 5) versus non-overweight (BCS 2 and 3), obese (BCS 5) versus non-overweight (BCS2 and 3) and an overall comparison between all four BCS (BCS 2, 3, 4 and 5) using a novel, validated HRQL instrument which is both web and mobile tablet / phone app based.
Our ability to measure pain in a valid and reliable way is a crucial component of effective pain management. Furthermore the current emphasis on evidence-based veterinary medicine requires that appropriate measures of clinical impact are developed and in that regard it is essential that instruments to monitor pain effectively in an individual, while providing data to enable the selection of treatments with know efficacy and impact are developed. In veterinary medicine, many pain scales have been constructed on an ad hoc basis, but the importance of applying rigorous methods to the development and testing of pain measures in order to ensure their validity and reliability is now recognised.
International Animal Health Journal
Recent advances in veterinary science mean that pharma companies can reap the benefits of health-related quality of life (HRQL) surveys and electronic data capture (EDC) for animal clinical trials, as well as those targeted at the human drug market too.